Effect of intravenous Mesna administration on alleviation of acute pancreatitis

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20121021011192N19

Enrollment

Registered

2024-11-02

Start date

2024-11-21

Completion date

Unknown

Last updated

2025-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with diagnosis of acute pancreatitis. Acute pancreatitis

Interventions

Intervention 1: Intervention group: receiving all necessary medications for treatment of acute pancreatitis on the basis of American college of gastroenterology plus administration of 400 mg/d mesna (

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Patients with diagnosis of acute pancreatitis on the basis of clinical symptoms Obtaining written informed consent

Exclusion criteria

Exclusion criteria: Patients with previous history of allergy to mesna

Design outcomes

Primary

Measure	Time frame
Decrease of CRP. Timepoint: 3 days after diagnosis of pancreatitis. Method of measurement: Laboratory evaluation.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammad Abbasinazari

Shahid Beheshti University of Medical Sciences

m_abbasi@sbmu.ac.ir+98 21 8887 3704

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026